發(fā)布時間：2018-06-19 06:00

  本文選題：漿液性癌 + 子宮內(nèi)膜樣癌��； 參考：《山西醫(yī)科大學(xué)》2014年碩士論文

【摘要】：目的：卵巢癌是女性最為常見的生殖系統(tǒng)惡性腫瘤之一,由于缺乏早期診斷手段,卵巢癌的死亡率居婦科惡性腫瘤之首。本實驗主要研究P53、ER, PR在卵巢漿液性癌和子宮內(nèi)膜樣癌的免疫組化表達情況,了解在卵巢癌發(fā)生發(fā)展中的作用,探討其表達及臨床病理學(xué)意義,進一步為臨床診斷、鑒別診斷及治療、預(yù)后提供確切的實驗室依據(jù)。 方法：收集山西省腫瘤醫(yī)院病理科2011-2013年卵巢癌組織標(biāo)本33例,其中漿液性癌20例,子宮內(nèi)膜樣癌13例,以上所有病例術(shù)前均未行放療、化療、免疫治療及激素治療。應(yīng)用免疫組化EnVision二步法對研究對象進行檢測,檢測P53、雌激素受體(ER)及孕激素受體(PR)在實驗標(biāo)本組織中的表達情況,計數(shù)結(jié)果應(yīng)用SPSS16.0統(tǒng)計軟件進行數(shù)據(jù)分析,X2檢驗及pearson相關(guān)分析,α=0.05為檢驗水準(zhǔn),p0.05,具有統(tǒng)計學(xué)意義,分析P53、 ER、PR在卵巢漿液性癌與子宮內(nèi)膜樣癌中的表達情況。 結(jié)果：1.P53在卵巢癌中的表達：病理分型中,漿液性癌P53的陽性表達率(80%)高于子宮內(nèi)膜樣癌(38.5%)(p0.05)；組織學(xué)分級中,低分化癌P53的陽性表達率(81%)高于中、高分化癌(33.3%)(p0.05)；臨床分期中,Ⅲ-Ⅳ期P53的陽性表達率(87.5%)高于Ⅰ-Ⅱ期(41.2%)(p0.05)。 2.ER在卵巢癌中的表達：病理分型中,子宮內(nèi)膜樣癌ER的陽性表達率(76.9%)高于漿液性癌(20%)(p0.05)；組織學(xué)分級中,中、高分化癌與低分化癌ER的陽性表達率分別為(58.3%、33.3%)(p0.05)；臨床分期中,Ⅰ-Ⅱ期ER的陽性表達率(64.7%)高于Ⅲ-Ⅳ期(18.8%)(p0.05)。 3.PR在卵巢癌中的表達：病理分型中,子宮內(nèi)膜樣癌PR的陽性表達率(69.2%)高于漿液性癌(15%)(p0.05)；組織學(xué)分級中,中、高分化癌與低分化癌PR的陽性表達率分別為(50%、28.6%)(p0.05)；臨床分期中,Ⅰ-Ⅱ期PR的陽性表達率(58.8%)高于Ⅲ-Ⅳ期(12.5%)(p0.05)。 4.ER與PR之間具有相關(guān)性,經(jīng)pearson相關(guān)性檢驗,相關(guān)系數(shù)r=0.632,p0.001。 結(jié)論：綜上述研究結(jié)果,我們得出以下結(jié)論： 1.P53表達與卵巢癌病理分型、組織學(xué)分級、臨床分期有關(guān),在漿液性癌中表達率高、在分化程度低、晚期卵巢癌中表達率高。 2. ER、PR表達與卵巢組織學(xué)分級無關(guān),與病理分型、臨床分期有關(guān),在子宮內(nèi)膜樣癌中表達率高,卵巢癌臨床分期越晚,ER, PR陽性表達率越低。 3. P53、ER、PR在卵巢漿液性癌與子宮內(nèi)膜樣癌中的表達不同,差異有統(tǒng)計學(xué)意義,聯(lián)合檢測P53、ER、PR的表達有助于非典型卵巢癌病變的診斷與鑒別診斷。 4.ER與PR之間呈正相關(guān),檢測ER、PR在早期卵巢癌中的表達較晚期陽性率高,有助于臨床判斷預(yù)后,指導(dǎo)治療。
[Abstract]:Objective: ovarian cancer is one of the most common malignant tumors of the reproductive system in women. The present study was designed to investigate the expression of P53 ERR and PR in ovarian serous carcinoma and endometrioid carcinoma, to understand the role of P53 ERR and PR in the carcinogenesis and development of ovarian cancer, and to explore the expression and clinicopathological significance of P53, PR for further clinical diagnosis. Differential diagnosis, treatment and prognosis provide accurate laboratory basis. Methods: 33 cases of ovarian cancer were collected from the Department of Pathology of Shanxi Cancer Hospital from 2011 to 2013, including 20 cases of serous carcinoma and 13 cases of endometrial carcinoma. All cases were not treated with radiotherapy, chemotherapy, immunotherapy and hormone therapy before operation. Immunohistochemical envision two-step method was used to detect the expression of p53, estrogen receptor ERR and progesterone receptor prednisone. The count results were analyzed by SPSS 16.0 statistical software for data analysis X _ 2 test and pearson correlation analysis. 偽 -0. 05 was the test level (p0.05), which had statistical significance. The expression of p53, ERP PR in ovarian serous carcinoma and endometrioid carcinoma was analyzed. Results 1. Expression of p53 in ovarian cancer: the positive expression rate of p53 in serous carcinoma was 80% higher than that in endometrial carcinoma (38.5%). In histological grade, the positive rate of p53 expression in poorly differentiated carcinoma was higher than that in moderately differentiated carcinoma (33. 3% p0. 05). The positive expression rate of p53 in stage 鈪，

本文編號：2038793